🚀 VC round data is live in beta, check it out!
Merus Valuation Multiples
Discover revenue and EBITDA valuation multiples for Merus and similar public comparables like Wantai BioPharm, Alkem Laboratories, Kelun, ABL Bio and more.
Merus Overview
About Merus
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
Founded
2003
HQ
Employees
260
Website
Sectors
Financials (FY)
EV
$7B
Merus Stock Performance
Merus has current market cap of $7B, and enterprise value of $7B.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $7B | $7B | — | XXX | XXX | XXX | — |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMerus Valuation Multiples
Merus Financial Valuation Multiples
As of March 7, 2026, Merus has market cap of $7B and EV of $7B.
Equity research analysts estimate Merus' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $7B | XXX | $7B | XXX | XXX | XXX |
| EV (current) | $7B | XXX | $7B | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Merus Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Merus Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Wantai BioPharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Alkem Laboratories | XXX | XXX | XXX | XXX | XXX | XXX |
| Kelun | XXX | XXX | XXX | XXX | XXX | XXX |
| ABL Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| PharmaEssentia | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Merus M&A Activity
Merus acquired XXX companies to date.
Last acquisition by Merus was on XXXXXXXX, XXXXX. Merus acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Merus
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialMerus Investment Activity
Merus invested in XXX companies to date.
Merus made its latest investment on XXXXXXXX, XXXXX. Merus invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Merus
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Merus
| When was Merus founded? | Merus was founded in 2003. |
| Where is Merus headquartered? | Merus is headquartered in Netherlands. |
| How many employees does Merus have? | As of today, Merus has over 260 employees. |
| Is Merus publicly listed? | Yes, Merus is a public company listed on Nasdaq. |
| What is the stock symbol of Merus? | Merus trades under MRUS ticker. |
| When did Merus go public? | Merus went public in 2016. |
| Who are competitors of Merus? | Merus main competitors are Wantai BioPharm, Alkem Laboratories, Kelun, ABL Bio. |
| What is the current market cap of Merus? | Merus' current market cap is $7B. |
| Is Merus profitable? | No, Merus is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.